Modified-Release Nifedipine
Katherine F. Croom,Keri Wellington,Katherine F Croom
DOI: https://doi.org/10.2165/00003495-200666040-00007
2006-01-01
Drugs
Abstract:AbstractNifedipine is a dihydropyridine calcium channel antagonist with predominantly vasodilatory activity. Modified-release formulations of nifedipine are effective antihypertensive and antianginal therapies and are generally well tolerated. Among the available formulations, those that produce a gradual increase in plasma nifedipine concentration, which is then sustained over a 24-hour period, are preferred, as they cause a gradual onset of vasodilatation and avoid baroreflex sympathetic activation (for example, nifedipine gastrointestinal therapeutic system [GITS] and a Japanese controlled-release formulation). Modified-release nifedipine had beneficial effects on a number of markers of vascular function, and nifedipine GITS reduced the need for coronary procedures in patients with coronary artery disease. In patients with hypertension, nifedipine GITS and nifedipine retard had beneficial effects on the overall incidence of major cardiovascular events, as did nifedipine retard in patients with concurrent hypertension and coronary artery disease.Pharmacological PropertiesThe primary pharmacodynamic effect of nifedipine is the dilatation of both large and small arteries, through a reduction in smooth muscle contraction in the arterial wall. Nifedipine has little effect on cardiac contractility or conduction. In addition to its vasodilatory actions, it also demonstrates antiatherosclerotic activity.Nifedipine is almost completely absorbed from the gastrointestinal tract after oral administration, undergoes first-pass metabolism in the liver and gut wall, and has oral bioavailability of 43–77%. It is highly plasma protein-bound. Nifedipine is metabolised in the liver to inactive metabolites, which are eliminated primarily in the urine; <1% of a dose is excreted unchanged in the urine.The haemodynamic response with nifedipine correlates with plasma concentration and the rate of change in plasma concentration. Rapid increases in plasma concentrations with the original immediate-release (short-acting) capsule, which was administered three times daily, led to an abrupt onset of vasodilatation that was associated with baroreflex sympathetic activation, commonly manifested as tachycardia. Modified-release formulations of nifedipine that provide a gradual increase to a moderate peak plasma level (accompanied by a gradual onset of vasodilatation) that is sustained over a 24-hour period, are not associated with baroreflex sympathetic activation. Examples include the once-daily nifedipine GITS formulation and a controlled-release formulation available in Japan.A number of other once-daily formulations of nifedipine are available, with different drug-release and plasma-concentration profiles. In addition, a marked food interaction occurs with some formulations but not others. Consequently, different once-daily formulations of nifedipine may have different effects on blood pressure (BP) and heart rate over a 24-hour period and, unless adequate data demonstrating similar profiles are available, they cannot be assumed to be equivalent in terms of their clinical effects.Therapeutic EfficacyIn patients with chronic stable angina pectoris, modified-release nifedipine (irrespective of formulation) significantly increased the time to onset of 0.1mV ST-segment depression during exercise testing compared with baseline. Improvements were similar to those seen with atenolol, carvedilol or diltiazem, although not as great as those seen with controlled-release metoprolol. In patients with an inadequate response to β-adrenoceptor antagonists, the addition of modified-release nifedipine significantly increased the time to 0.1mV ST-segment depression compared with atenolol monotherapy and increased it to a greater extent than seen with the addition of modified-release isosorbide mono- or dinitrate. Modified-release nifedipine was as effective as modified-release isosorbide dinitrate or nisoldipine coat-core in patients with variant angina.In adults with essential hypertension, monotherapy with modified-release nifedipine (irrespective of formulation) for ≥8 weeks led to similar reductions in systolic and diastolic BP, and achieved similar response rates, to those seen with comparator agents, including amlodipine, lacidipine, extended-release verapamil, enalapril, lisinopril, losartan (with or without hydrochlorothiazide) and nebivolol. In one trial, nifedipine retard reduced systolic, but not diastolic, BP more than atenolol. In INSIGHT, nifedipine GITS and hydrochlorothiazide/amiloride (co-amilozide) reduced mean 24-hour BP to a similar extent. The antihypertensive efficacy of modified-release nifedipine formulations was similar to that of lercanidipine, fosinopril, losartan (with or without hydrochlorothiazide) and amlodipine in elderly patients; to that of amlodipine and captopril plus hydrochlorothiazide in Black patients; and to that of telmisartan or lisinopril in diabetic patients. The combination of nifedipine GITS plus losartan reduced systolic and diastolic BP more than losartan monotherapy and reduced systolic (but not diastolic) BP more than nifedipine GITS monotherapy. In patients with an inadequate response to candesartan, atenolol or diuretic monotherapy, the addition of modified-release nifedipine formulations led to significant reductions in BP.Several studies have assessed the effects of modified-release nifedipine on end organs. When considering vascular function, substudies of INSIGHT and the ENCORE trials showed that nifedipine GITS slowed the progression of carotid intima-media thickening and coronary calcification and improved endothelial function in patients with cardiovascular disease. Nifedipine retard slowed the angiographic progression of atherosclerosis, particularly in mild to moderate stenosis, in a JMIC-B substudy. In patients with left ventricular (LV) hypertrophy, nifedipine GITS reduced LV mass index to a similar extent as an ACE inhibitor in the PRESERVE trial. Renal function was better preserved with nifedipine GITS than with co-amilozide in hypertensive patients in INSIGHT, while in J-MIND, nifedipine retard had a similar effect on urinary albumin excretion (UAE) rate after 2 years to that seen with enalapril in hypertensive diabetic patients. A low-dose combination of the Japanese controlled-release formulation plus candesartan reduced UAE to a greater extent than candesartan monotherapy in hypertensive patients with microalbuminuria.Modified-release nifedipine has been evaluated in several large clinical outcome trials in patients with hypertension or coronary artery disease. Nifedipine GITS had similar efficacy to co-amilozide in terms of reducing the overall incidence of major cardiovascular complications in hypertensive patients with at least one other cardiovascular risk factor (INSIGHT). In patients with chronic stable angina (ACTION), the addition of nifedipine GITS to standard therapy (including β-adrenoceptor antagonists and lipid-lowering agents) did not significantly reduce the incidence of a composite of major cardiovascular events compared with the addition of placebo, but did reduce the incidence of a composite secondary endpoint (any death, cardiovascular event or procedure), largely because of a reduced need for coronary procedures. In the subgroup of patients with hypertension as well as coronary artery disease, nifedipine GITS significantly reduced the risk of major cardiovascular events compared with placebo. Nifedipine retard significantly reduced the risk of major clinical events compared with placebo in elderly hypertensive patients (STONE), and had similar efficacy to ACE-inhibitor therapy in terms of reducing major cardiac events in patients with both hypertension and coronary artery disease (JMIC-B).TolerabilityModified-release formulations of nifedipine are generally well tolerated. The most common types of adverse event seen, irrespective of formulation, are those relating to its vasodilatory properties, such as headache, peripheral oedema not associated with heart failure, flushing and palpitations.In contrast to the original, immediate-release capsule formulation which was associated with baroreflex sympathetic activation, generally expressed as tachycardia, modified-release formulations are designed to produce a more gradual change in BP and reduce sympathetic activation. Nifedipine retard went some way towards addressing this issue, but can still be associated with changes in heart rate, whereas some once-daily formulations, such as the nifedipine GITS and the Japanese controlled-release formulations, are not associated with baroreflex sympathetic activation and tachycardia. Concerns that the immediate-release capsule might be associated with an increase in mortality have not been extended to modified-release formulations; large outcome trials have demonstrated that nifedipine GITS and nifedipine retard do not have an adverse effect on overall clinical outcomes in hypertensive or coronary artery disease patients.
pharmacology & pharmacy,toxicology